Trending Now
GeoVax Labs (GOVX) surges on positive sentiment
Shares of GeoVax Labs (GOVX) traded as high as $6.19 with more than 11.4M shares exchanging hands at 11:00 am EST. GeoVax...
GameStop (NYSE:GME) shorts could to be crushed by Apes
GameStop (NYSE:GME) reported a surprise profit in the fiscal fourth quarter, with earnings of 16 cents a share compared to a loss...
Axon Enterprise Inc (NASDAQ:AXON) keep surging and here’s why
Despite prevalent macroeconomic concerns in 2023, Axon Enterprise (NASDAQ: AAXN), the Taser manufacturer, continues to thrive, making it a standout stock for...
Popular News
Oncternal Therapeutics Inc. (NASDAQ:ONCT) Provides Updates On Cirmtuzumab In Combination With...
Oncternal Therapeutics Inc. (NASDAQ:ONCT) has provided a corporate update and released third-quarter 2020 results.
Oncternal to offer data updates for MCL, CLL, and Ewing sarcoma...
MAKE IT MODERN
LATEST REVIEWS
MannKind Corporation (NASDAQ:MNKD) Reports 27% YoY Growth In Afrezza Revenue In...
MannKind Corporation (NASDAQ:MNKD) has released its financial results for the third quarter and nine months ended September 30, 2020.
MannKind continues to execute well as...
MAKE IT MODERN
PERFORMANCE TRAINING
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has Acquired New R&D Center
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) announced that the group had acquired a new research and development center, measuring close to 48,000 square feet;...
MannKind Corporation (NASDAQ:MNKD) Presents Encouraging Afrezza Clinical Study Data At The ADA Virtual Scientific...
MannKind Corporation (NASDAQ:MNKD) has announced new Afrezzza Inhalation powder clinical study results. The company presented the data at this year’s American Diabetes Associations 80th...
Creative Medical Technology Holdings Inc (CELZ) could double from current levels
Creative Medical Technology Holdings Inc (CELZ) last traded at $1.0400, a gain of +0.5281 (+103.16%). More than 137M shares exchanged hands compared...
Dare Biosciences Inc. (NASDAQ:DARE) Reports Positive DARE-BV1 Study Results In Bacterial Vaginosis Treatment
Dare Biosciences Inc. (NASDAQ:DARE) has announced encouraging top-line DARE-BVFREE Third Phase double-blinded, randomized, placebo-controlled clinical study results. The study evaluated the company's DARE-BV1 in...
Codexis Inc. (NASDAQ: CDXS) Receives Orphan Drug Designation For CD-6512 in Homocystinuria Treatment
Codexis Inc. (NASDAQ: CDXS) has announced that the FDA has granted its CDX-6512 drug candidate an orphan drug designation in homocystinuria treatment.
CDX-6512 has the...
MAKE IT MODERN
[/tdc_zone]